Efficacy and safety of naltrexone use in pediatric patients with autistic disorder

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1086-1095

  Elchaar, Gladys M ^a,b   Maisch, Nicole M ^a,c   Gianni Augusto, Laura M ^a,b   Wehring, Heidi J ^a,d  

^a ST JOHN'S UNIVERSITY   (United States)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Autism; Autistic disorder; Naltrexone; Pediatrics

Indexed keywords

NALTREXONE;

AGITATION; ANGER; ANOREXIA; AUTISM; AUTOMUTILATION; BITTER TASTE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CRYING; DEHYDRATION; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERACTIVITY; INFORMATION RETRIEVAL; INTERNATIONAL PHARMACEUTICAL ABSTRACTS; IRRITABILITY; LASSITUDE; MEDLINE; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; REFERENCE DATABASE; REVIEW; SEDATION; SIDE EFFECT; STEREOTYPY; VISUAL IMPAIRMENT; VOMITING;

AUTISTIC DISORDER; CHILD; CLINICAL TRIALS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; SELF-INJURIOUS BEHAVIOR;

EID: 33745115657     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G499     Document Type: Review

References (39)

1. First MB, ed. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
2. Streck M. Autism spectrum disorders (pervasive developmental disorders). NIH publication no. NIH-04-5511. Bethesda, MD: National Institute of Mental Health, National Institutes of Health, US Department of Health and Human Resources. 2004. www.nimh.nih.gov/publicat/autism.cfm (accessed 2004 Jan 20).
3. Fombonne E. The epidemiology of autism: a review. Psychol Med 1999;29:769-86.
4. Burd L, Fisher W, Kerbeshian J. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatry 1987;26:700-3.
5. Ritvo ER, Freeman BJ, Pingree C, et al. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry 1989;146:194-9.
6. Kirby RS, Brewster MA, Canino CU, Pavin M. Early childhood surveillance of developmental disorders by a birth defects surveillance system: methods, prevalence, comparisons, and mortality patterns. J Dev Behav Pediatr 1995;16:318-26.
7. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001;108:1155-61.
8. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA 2003;289:49-55.
9. Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics 2005;115: e277-82.
10. Palermo MT, Curatolo P. Pharmacologic treatment of autism. J Child Neurol 2004;19:155-64.
11. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003;64(suppl 4):16-25.
12. Panksepp J. A neurochemical theory of autism. Trends Neurochem Sci 1979;2:174-7.
13. Herman BH, Hammock MK, Arthur-Smith A, et al. Naltrexone decreases self-injurious behavior. Ann Neurol 1987;22:550-2.
14. Leboyer M, Bouvard MP, Dugas M. Effects of naltrexone on infantile autism (letter). Lancet 1988;1:715.
15. Campbell M, Adams P, Small AM, Tesch LM, Curren EL. Naltrexone in infantile autism. Psychopharmacol Bull 1988;24:135-9.
16. Campbell M, Overall JE, Small AM, et al. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989;28:200-6.
17. Herman BH, Hammock MK, Arthur-Smith A, Kuehl K, Appelgate K. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children. Dev Pharmacol Ther 1989;12:118-27.
18. Barrett RP, Feinstem C, Hole WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989;93:644-51.
19. Walters AS, Barrett RP, Feinstein C, Mercurio A, Hole WT. A case report of naltrexone treatment of self-injury and social withdrawal in autism. J Autism Dev Disord 1990;20:169-76.
20. Panksepp J, Lensing P. Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children. J Autism Dev Disord 1991;21:243-9.
21. Lensing P, Klingler D, Lampl C, et al. Naltrexone open trial with a 5-year-old-boy. A social rebound reaction. Acta Paedopsychiatr 1992;55:169-73.
22. Akkok F. The effects of naltrexone in autistic children: report of two cases. Turk J Pediatr 1995;37:19-23.
23. Williams PG, Allard A, Sears L, et al. Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management. J Autism Dev Disord 2001;31:103-8.
24. Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Chorocco MC. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990;26:130-5.
25. Leboyer M, Bouvard MP, Launay J, et al. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992;22:309-19.
26. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32:1283-91.
27. Ernst M, Devi L, Silva RR, et al. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221-7.
28. Gonzalez NM, Campbell M, Small AM, et al. Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacol Bull 1994;30:203-8.
29. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995;58:203-15.
30. Bouvard MP, Leboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 1995;58:191-201.
31. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995;34:223-31.
32. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996;39:1023-31.
33. Scifo R, Cioni M, Nicolosi A, et al. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann 1st Super Sanita 1996;32:351-9.
34. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570-8.
35. Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P, Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol 1999;9:361-6.
36. Feldman HM, Kosmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999;38:587-93.
37. Willemsen-Swinkels SHN, Buitelaar JK, van Berckelaer-Onnes IA, van Engeland H. Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J Autism Dev Disord 1999;29:167-9.
38. Buitelaar JK, Willemsen-Swinkels S, van Engeland H. Naltrexone in children with autism. J Am Acad Child Adolesc Psychiatry 1998;37:800-2.
39. Fawcett JP, Morgan NC, Woods DJ. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone. Ann Pharmacother 1997;31:1291-5.